Yilmaz A T, Demírkiliç U, Arslan M, Kurulay E, Ozal E, Tatar H, Oztürk O
Department of Cardiovascular Surgery, Gülhane Military Medical Academy, Ankara, Turkey.
J Card Surg. 1996 Jan-Feb;11(1):61-4. doi: 10.1111/j.1540-8191.1996.tb00010.x.
To evaluate the necessity and efficacy of quinidine fumarate, verapimil, or amiodarone prophylaxis for sinus rhythm maintenance in patients who experienced atrial fibrillation after coronary artery bypass surgery.
Between 1992 and 1995, this prospective, randomized, placebo-controlled study examined 120 patients in whom atrial fibrillation occurred and was restored to sinus rhythm by pharmacological therapy or direct current cardioversion in the immediately postoperative period after coronary artery by-pass surgery. There were no significant differences in perioperative characteristics among the patients, who were randomly separated into four groups in the course of discharge. In group 1 (n = 30), patients did not receive antiarrhythmic drugs. Quinidine fumarate was given in group 2 (n = 30), verapimil in group 3 (n = 30), and amiodarone in group 4 (n = 30). Patients were monitored six times over a 90-day postoperative period by 24-hour Holter monitoring and routine examination.
The recurrent atrial fibrillation usually developed within 15 days of discharge. Atrial fibrillation occurred in one patient (3.33%) in group 1, and two each (6.66%) in groups 2, 3, and 4. Atrial fibrillation was asymptomatic and occurred with slow ventricular response in groups 3 and 4. Side effects occurred in 5 patients (16.6%) given quinidine, 1 patient given amiodarone, but in no patient given verapimil.
There were no significant differences in the maintenance of sinus rhythm among the four groups, so we suggest that long-term prevention of atrial fibrillation in patients with coronary artery bypass grafting was not necessary at the postdischarge period.
评估富马酸奎尼丁、维拉帕米或胺碘酮预防冠状动脉搭桥术后发生房颤患者维持窦性心律的必要性和疗效。
1992年至1995年期间,这项前瞻性、随机、安慰剂对照研究纳入了120例在冠状动脉搭桥术后即刻出现房颤并通过药物治疗或直流电复律恢复窦性心律的患者。患者围手术期特征无显著差异,在出院过程中随机分为四组。第1组(n = 30)患者未接受抗心律失常药物治疗。第2组(n = 30)给予富马酸奎尼丁,第3组(n = 30)给予维拉帕米,第4组(n = 30)给予胺碘酮。术后90天内通过24小时动态心电图监测和常规检查对患者进行6次监测。
复发性房颤通常在出院后15天内发生。第1组有1例患者(3.33%)发生房颤,第2、3、4组各有2例患者(6.66%)发生房颤。第3组和第4组的房颤无症状,且心室反应缓慢。服用奎尼丁的患者中有5例(16.6%)出现副作用,服用胺碘酮的患者中有1例出现副作用,而服用维拉帕米的患者未出现副作用。
四组在维持窦性心律方面无显著差异,因此我们认为在出院后阶段对冠状动脉搭桥术患者进行房颤的长期预防没有必要。